drugset
drugset / Trial / NCT06532058

Phase IIa Study to Assess Safety and Efficacy in the Relapsed/Refractory Acute Myeloid Leukemia

NCT06532058 ↗

Phase 2 Recruiting 53 enrolled Changzhou Qianhong Bio-pharma Co., Ltd.
RandomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to assess the safety and efficacy of QHRD107 capsule combined with Venclexta and azacitidine in the treatment of relapsed/refractory acute myeloid leukemia: a single-arm, open, multicenter Phase IIa study

Timeline

Start
2023-08-10
Primary completion
2025-02-10
Completion
2025-05-10

Drugs

EvaluationDrugModalityDoseRoute
Subject QHRD107 Unknown 40 mg Oral
Subject QHRD107 Unknown 60 mg Oral
Subject QHRD107 Unknown 80 mg Oral
Background Azacitidine Other / unclassified — Subcutaneous
Background Venetoclax Small molecule — Oral

Indications

acute myeloid leukemia